Perpetual Ltd Invests $1.52 Million in Smith & Nephew SNATS, Inc. $SNN

Perpetual Ltd acquired a new stake in Smith & Nephew SNATS, Inc. (NYSE:SNN) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 46,262 shares of the medical equipment provider’s stock, valued at approximately $1,518,000.

Several other institutional investors have also recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd purchased a new position in Smith & Nephew SNATS during the third quarter worth about $41,000. Northwestern Mutual Wealth Management Co. grew its holdings in Smith & Nephew SNATS by 105.8% in the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 1,385 shares of the medical equipment provider’s stock valued at $50,000 after buying an additional 712 shares during the period. Huntington National Bank grew its holdings in Smith & Nephew SNATS by 1,837.0% in the 3rd quarter. Huntington National Bank now owns 1,414 shares of the medical equipment provider’s stock valued at $51,000 after buying an additional 1,341 shares during the period. Smartleaf Asset Management LLC increased its stake in shares of Smith & Nephew SNATS by 1,222.3% during the 3rd quarter. Smartleaf Asset Management LLC now owns 2,486 shares of the medical equipment provider’s stock valued at $88,000 after acquiring an additional 2,298 shares during the last quarter. Finally, Root Financial Partners LLC acquired a new position in shares of Smith & Nephew SNATS during the 3rd quarter valued at about $102,000. 25.64% of the stock is currently owned by institutional investors and hedge funds.

Smith & Nephew SNATS Trading Up 0.0%

NYSE SNN opened at $32.15 on Friday. Smith & Nephew SNATS, Inc. has a one year low of $23.91 and a one year high of $38.79. The company’s 50 day moving average price is $34.20 and its 200 day moving average price is $34.21. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.25 and a current ratio of 2.57.

Smith & Nephew SNATS (NYSE:SNN) last released its quarterly earnings data on Tuesday, February 17th. The medical equipment provider reported $29.55 earnings per share (EPS) for the quarter. The business had revenue of $1.60 billion for the quarter. As a group, equities research analysts forecast that Smith & Nephew SNATS, Inc. will post 1.69 earnings per share for the current fiscal year.

Smith & Nephew SNATS Dividend Announcement

The firm also recently declared a dividend, which will be paid on Wednesday, May 27th. Investors of record on Friday, March 27th will be given a dividend of $0.482 per share. This represents a yield of 304.0%. The ex-dividend date of this dividend is Friday, March 27th.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on SNN. Weiss Ratings reissued a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research report on Wednesday, January 21st. Canaccord Genuity Group increased their price target on shares of Smith & Nephew SNATS from $34.00 to $35.00 and gave the stock a “hold” rating in a research note on Thursday, March 5th. Royal Bank Of Canada downgraded Smith & Nephew SNATS from an “outperform” rating to a “sector perform” rating in a report on Monday, December 15th. Finally, Wall Street Zen raised Smith & Nephew SNATS from a “buy” rating to a “strong-buy” rating in a research report on Sunday, March 29th. One investment analyst has rated the stock with a Strong Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $36.25.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.